Van Abel Amy L, Virk Abinash, Cole Kristin, Lane Trudi, Osmon Douglas, Pertzborn Margaret, Schreier Diana, Teaford Hilary, Willis Courtney, Woods Anna, Rivera Christina G
Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.
Antimicrob Steward Healthc Epidemiol. 2024 Aug 7;4(1):e111. doi: 10.1017/ash.2024.348. eCollection 2024.
The primary objective was to determine the rate of clinical actions taken post-discharge on updated microbiology results by an ID pharmacist-led team. Secondary objectives were to describe the microbiology results requiring intervention, characterize interventions by type and severity, and determine time from result to clinical review.
Retrospective cohort study.
Four hospitals within Mayo Clinic, including two large academic centers and two Mayo Clinic Health System sites.
Adult patients at four sites within Mayo Clinic from 1/1/2019 to 2/28/2023. Eligible patients had a hospitalization with an ID consult and an updated microbiology result reported after discharge.
Pharmacists reviewed a report of selected patients with microbiology tests that resulted post-discharge within the last 24-96 hours. Interventions were recorded electronically in real-time by the pharmacist. Of those patient encounters with an intervention, a sample of 200 patient encounters was randomly selected for detailed chart abstraction.
A total of 6,792 encounters with at least one microbiology result reviewed post-discharge were identified. Of these encounters, 1977 (29%) had at least one resulting intervention. Median time from test update to clinical review was 27.2 hours (IQR 21.6-69.6). The highest severity ratings, in which failure to intervene may have resulted in patient harm, were assigned to the intervention in 28% of cases.
For patients seen by an inpatient ID consult service, a post-hospital discharge microbiology result review process performed by ID-trained pharmacists effectively addressed abnormal results during the transition of care. Similar processes may be considered at other institutions.
主要目的是确定由感染病科药剂师主导的团队在出院后根据更新的微生物学结果采取临床行动的比率。次要目的是描述需要干预的微生物学结果,按类型和严重程度对干预措施进行特征描述,并确定从结果报告到临床评估的时间。
回顾性队列研究。
梅奥诊所的四家医院,包括两个大型学术中心和两个梅奥诊所医疗系统站点。
2019年1月1日至2023年2月28日期间梅奥诊所四个站点的成年患者。符合条件的患者需有住院期间感染病科会诊记录且出院后有更新的微生物学结果报告。
药剂师审查了一份在过去24 - 96小时内出院后微生物学检测结果的选定患者报告。药剂师实时以电子方式记录干预措施。在那些有干预措施的患者就诊记录中,随机抽取200例患者就诊记录进行详细病历摘要分析。
共识别出6792例出院后至少有一项微生物学结果被审查的就诊记录。在这些就诊记录中,1977例(29%)至少有一项后续干预措施。从检测结果更新到临床评估的中位时间为27.2小时(四分位间距21.6 - 69.6小时)。28%的干预措施被评定为最高严重等级,即不进行干预可能会对患者造成伤害。
对于接受住院感染病科会诊服务的患者,由经过感染病培训的药剂师进行的出院后微生物学结果审查流程在护理过渡期间有效处理了异常结果。其他机构可考虑采用类似流程。